Mark C. Walters

City College of San Francisco — United States

Medicine · Health Sciences

48h-index10.6kcitations255works13.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemoglobinopathies and Related Disorders(175), Prenatal Screening and Diagnostics(78), Hematopoietic Stem Cell Transplantation(67), Acute Myeloid Leukemia Research(30), Acute Lymphoblastic Leukemia research(28)

Publications255 total

Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507
Blood·2025Open Access
Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Blood·2025Open Access
First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises
Blood·2025
Synthetic oligonucleotides contain synthesis errors that are propagated into the genome by editing through homology-directed repair
Blood·2025Open Access
CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trial
Blood·2025Open Access
Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT
Molecular Therapy·2025Open Access
Synthesis errors in oligonucleotides are propagated into the genome by homology-directed repair
2025· 1 citedOpen Access
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
NEJM Evidence·2025· 23 citedOpen Access
Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent β-Thalassemia
Transplantation and Cellular Therapy·2025· 1 cited
Durable Clinical Benefits in Severe Sickle Cell Disease with Exagamglogene Autotemcel
Transplantation and Cellular Therapy·2025
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial
Transplantation and Cellular Therapy·2025
An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
Transplantation and Cellular Therapy·2025Open Access
Hematopoietic Cell Transplant compared with Standard Care in Adolescents and Young Adults with Sickle Cell Disease.
UNC Libraries·2024Open Access
Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
Blood·2024· 2 citedOpen Access
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial
Blood·2024· 1 cited
An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
Blood·2024· 7 citedOpen Access
Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
Blood·2024· 2 cited
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial
Blood·2024· 5 cited
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
The Lancet·2024· 32 cited
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Blood Advances·2024· 5 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Mary Eapen(11), Keith M. Sullivan(9), Shalini Shenoy(9), David I. K. Martin(8), John F. Tisdale(8), Françoise Bernaudin(7), Lakshmanan Krishnamurti(7), Monica Bhatia(7), Naynesh Kamani(7), Irene Roberts(6), Julie Kanter(6), Alexis A. Thompson(5), Mohammed Asmal(5), Wendy Magis(5), Éliane Gluckman(5), David M. Margolis(5), John E. Wagner(5), Julie A. Panepinto(5), John E. Levine(5), Michael A. Pulsipher(5)